Pathology (PSR)

病理学（PSR）

• 批准号: 10554265
• 负责人: Gregory James Tsongalis
• 金额: $ 10.88万
• 依托单位: DARTMOUTH COLLEGE
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-08-04 至 2024-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10554265
• 关键词: Accreditation; Acute Myelocytic Leukemia; Adult; Biological Assay; Biological Markers; Budgets; CLIA certified; Cancer Center Support Grant; Cell Therapy; Childhood; Clinical; Clinical Data; Clinical Trials; Computer software; Data; Databases; Environment; Funding; Gastrointestinal Stromal Tumors; Gene Mutation; Genes; Genomics; Glioma; Histology; Human; Immunofluorescence Immunologic; Institution; Ions; Laboratories; Malignant Neoplasms; Medicine; Metastatic Melanoma; Mutation; Myelogenous; Non-Small-Cell Lung Carcinoma; Norris Cotton Cancer Center; Oncogenes; Pathology; Patients; Physicians; Publications; Research; Research Personnel; Resource Sharing; Role; Sampling; Scientist; Services; Solid Neoplasm; Somatic Mutation; Specimen; System; Technology; Testing; Translational Research; biobank; biomarker development; biomarker discovery; cell free DNA; data mining; data warehouse; design; fusion gene; gene panel; gene therapy; genomic data; member; metastatic colorectal; multidisciplinary; next generation sequencing; personalized medicine; programs; research clinical testing; sarcoma; targeted treatment; triple-negative invasive breast carcinoma; tumor

Project Summary/Abstract: Pathology The Pathology Shared Resource (PSR), a designated Norris Cotton Cancer Center (NCCC) Shared Resource facility, was created to provide NCCC investigators access to the latest technologies for biobanking and biomarker testing in a CLIA-licensed, CAP-accredited laboratory environment. The CLIA/CAP standards are essential to the support of clinical trials, biomarker discovery studies, and the transition of research findings to clinical testing. The PSR is housed under the umbrella of the laboratory for Clinical Genomics and Advanced Technology (CGAT) in the Department of Pathology and Laboratory Medicine. Major PSR services span histology, genomics, cell therapy, and the institutional biorepository. Since the last review, the Shared Resource has moved into 10,000 sf of new space in the Williamson Translational Research Building. The lab acquired an Ion Torrent Chef-55 system to support its role as a central reference lab for both the adult and pediatric NCI MATCH trials. Next generation sequencing services now include a 50-gene cancer hotspot panel, a 50-gene solid tumor fusion gene panel, and a 54-gene myeloid panel, resulting in a somatic mutation database of more than 4,000 patient tumors now available for investigator-initiated data mining. For the Adult MATCH trial, the laboratory has sequenced 280 samples, and for the Pediatric MATCH trial we have sequenced 292 samples to date. The PSR has established a somatic mutation database for routinely tested human cancers that includes glioma, triple negative breast cancer, non-small cell lung cancer, metastatic colorectal cancer, metastatic melanoma, gastrointestinal stromal tumor, sarcoma, and acute myeloid leukemia. These data have resulted in numerous multidisciplinary publications evaluating mutation profiles within and across tumor types. Institutional biorepository samples are annotated in eSample, a module of Velos which is supported by the NCCC and has connectivity with the clinical trial program eResearch, also a module in Velos. I2B2 connectivity will facilitate the design of targeted therapies in personalized medicine. Since 2014, PSR has provided over 20,000 units of service to 60 current NCCC Members across all four Programs. Funded NCCC Members since 2015 have represented 77% (49) of Total Users, and we are requesting only 38% of the Total PSR budget from CCSG support. Additional multiplex IHC assays, immunofluorescence and expanded gene mutation panels are being developed to further support more advanced investigator-driven applications. In addition, the laboratory continues to develop cell-free DNA assays and expand the institutional biorepository with implementation of the BC Platform specimen/data warehousing software that will allow investigators portal access to Independent Bill Review (IBR) specimens curated with clinical and genomic data.

项目总结/摘要：病理学 病理学共享资源（PSR），指定的诺里斯棉花癌症中心（NCCC）共享资源 设施，旨在为NCCC调查人员提供最新的生物库技术， 在CLIA许可、CAP认证的实验室环境中进行生物标志物检测。CLIA/CAP标准 对于支持临床试验、生物标志物发现研究以及将研究结果转化为 临床试验PSR位于临床基因组学和高级生物技术实验室的保护伞下。 病理学和实验室医学系的技术（CGAT）。主要PSR服务范围 组织学、基因组学、细胞治疗和机构生物储存库。自上次审查以来， 资源已搬进10,000平方英尺的新空间在威廉姆森翻译研究大楼。实验室 获得了Ion Torrent Chef-55系统，以支持其作为成人和 儿科NCI MATCH试验。下一代测序服务现在包括50个基因的癌症热点 一组50个基因的实体瘤融合基因组和一组54个基因的髓样基因组，导致体细胞突变 目前，超过4，000名患者肿瘤的数据库可用于肿瘤发生器启动的数据挖掘。成人 MATCH试验，实验室已经测序了280个样本，对于儿科MATCH试验，我们有 迄今为止已对292个样本进行了测序。PSR建立了一个体细胞突变数据库，用于常规检测 人类癌症，包括神经胶质瘤、三阴性乳腺癌、非小细胞肺癌、转移性 结肠直肠癌、转移性黑素瘤、胃肠道间质瘤、肉瘤和急性髓性白血病。 这些数据导致了许多多学科的出版物， 肿瘤类型之间的差异。机构生物贮藏库样品在eSample中注释，eSample是Velos的一个模块， 由NCCC支持，并与临床试验程序eResearch连接，也是Velos中的一个模块。 I2 B2连接将促进个性化医疗中靶向治疗的设计。自2014年以来，PSR 在所有四个项目中，为60名NCCC现有会员提供了20，000多项服务。资助NCCC 自2015年以来，会员已占总用户的77%（49），而我们只要求总数的38% 来自CCSG支持的PSR预算。额外的多重IHC检测、免疫荧光和扩增基因 目前正在开发突变面板，以进一步支持更先进的突变器驱动应用。在 此外，该实验室还在继续开发无细胞DNA检测方法，并扩大机构生物库 实施业连平台样本/数据仓储软件，使调查人员能够 访问由临床和基因组数据管理的独立账单审查（IBR）标本。